Current COVID-19 Medication Therapy

BA.2 variant represents more than 50% of new COVID-19 cases in NYS (as of Mar 28, 2022)

Infusion COVID-19 Treatments

Treatment for patients with mild to moderate COVID-19 at high risk of progressing to severe disease within 7 of symptom onset who are not hospitalized due to COVID-19. The choice of first line treatment should be based on the current prevalence and effectiveness against the variant circulating at the time of prescribing.

Therapy	Indication	Dose *Require 1 hour observation after administration*	Location Availability	Date for IT Build & Implementation
BEBTELOVIMAB	**First line** treatment while BA.2 is the dominant strain for ages 12 years and older	175 mg IV Push injection once Administer over at least 30 seconds	WICC – St. Mary's Campus Wilson Center – RGH Campus ED Treat and Release	3/31/22
REMDESIVIR	**Second line** treatment for ages 12 years and older if alternative options are inaccessible or clinically inappropriate‡	Day 1: 200 mg IV infusion Day 2: 100 mg IV infusion Day 3: 100 mg IV infusion Administer over 30 – 120 minutes	ED Border and Inpatient settings	1/12/22

‡Weight-based dosing for patients less than 12 years of age weighing at least 3.5 kg (see EUA)

Oral Antiviral Treatments

Treatment for nonhospitalized patients with mild to moderate COVID-19 at high risk of progressing to severe disease within 5 days of symptom onset.

Therapy	Indication	Dose	Location Availability	Date for IT Build & Implementation
NIRMATRELVIR PLUS RITONAVIR (PAXLOVID)	**First line** outpatient treatment for ages 12 years and older	2 nirmatrelvir 150 mg tablets + 1 ritonavir 100 mg tablet Twice daily for 5 days	See website below *Require outpatient prescription*	1/7/22
MOLNUPIRAVIR (LAGEVRIO)	**Second line** outpatient treatment for ages 18 years and older if alternative options are inaccessible or clinically inappropriate	4 molnupiravir 200 mg capsules Every 12 hours for 5 days	See website below *Require outpatient prescription*	1/7/22

Prophylactic Injectable Monoclonal Antibodies

Pre-exposure prophylaxis for patients with moderate to severely compromised immune systems who may not mount an adequate response to immunization or those who have a history of serious adverse reactions to COVID-19 vaccination. In any patient who received a COVID-19 vaccination, wait at least 2 weeks to administer Evusheld.

Therapy	Indication	Dose *Requires 1 hour observation after administration*	Location Availability	Date for IT Build & Implementation
TIXAGEVIMAB PLUS CILGAVIMAB (EVUSHELD)	Outpatient prophylaxis for ages 12 years and older	tixagevimab 300 mg IM injection + cilgavimab 300 mg IM injection Given consecutively once^	AIR Infusion Center Heme/Onc Infusion Center – St. Mary's Heme/Onc Infusion Center- RGH	1/14/22

^Preferably administer one in each of the gluteal muscles. Can repeat dose every 6 months. For patients who have previously received a dose of tixagevimab 150 mg plus cilgavimab 150 mg, the FDA EUA states that a second dose of tixagevimab 150 mg plus cilgavimab 150 mg should be given as soon as possible.

To check the availability of COVID-19 therapies in the area, click the following link and enter zip code https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/

1. CDC COVID-19 Data tracker [Internet]. Centers for Disease Control and Prevention; [cited 2022Mar28]. Available from: https://covid.cdc.gov/covid-data-tracker
2. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. [Accessed 2022Mar28].
3. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Bebtelovimab. 2022 March 25; Available at: https://www.fda.gov/media/156152/download
4. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Remdesivir. 2022 January 21; Available at: https://www.fda.gov/media/137566/download
5. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. 2022 March 18; Available at: https://www.fda.gov/media/155050/download
6. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir. 2022 March 23; Available at: https://www.fda.gov/media/155054/download
7. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld. 2022 February 24; Available at: https://www.fda.gov/media/154701/download
8. FDA authorizes revisions to Evusheld dosing [Internet]. U.S. Food and Drug Administration. FDA; 2022 [cited 2022Mar28]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing